Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
As Curtain Rises on Diet, MHLW Aims to Get Amended PMD Bill Enacted in Early November
To read the full story
Related Article
- Japan Sets 1st Rollout of Amended PMD Law for Sept. 1
March 9, 2020
- Amended PMD Law Promulgated, 3-Step Enforcement to Begin Next Year
December 5, 2019
- Amended PMD Law Set for 3-Step Enforcement, 1st Execution Eyed Next Autumn
November 28, 2019
- Japan Enacts Amended Pharmaceuticals and Medical Devices Law
November 27, 2019
- Upper House Panel Discusses PMD Law Amendment Bill, Another Session Set for Nov. 26
November 22, 2019
- Lower House OKs PMD Law Amendment Bill
November 15, 2019
- PMD Law Amendment Bill Clears Lower House Health Panel
November 14, 2019
- Substantive Diet Discussions Get Underway for PMD Law Amendment
November 7, 2019
- Discussions on PMD Law Amendment Bill Start in Extraordinary Diet
October 24, 2019
REGULATORY
- MHLW Generic Panel Outlines Plan to Drive Industry Revamp within Specific Time Frame
March 28, 2024
- Japan’s HIV, AIDS Cases Rebound in 2023 after COVID
March 28, 2024
- Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
March 28, 2024
- Japan Approves Piasky, Beyfortus, Broader Use for Abrysvo, and Lot More
March 27, 2024
- PMDA Chief Fujiwara to Remain Skipper for Another Term
March 27, 2024
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…